MHRA approves deuruxolitinib (Leqselvi) for severe alopecia areata in adults
Start here
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults. The regulator says it will keep the medicine's safety and effectiveness under close review following approval. The decision gives adults in the UK with severe alopecia areata a new treatment option. Ongoing post-approval monitoring by the MHRA continues.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- gov.ukMHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (brand name Leqselvi) to treat severe alopecia areata in adults, and says it will keep the safety and effectiveness of the medicine under close review.
Heat trend for this story
Heat now 6·Peak in the comparable set 10 (Oct 24 01:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.